Aflac Earnings Call Transcripts
Fiscal Year 2026
-
Innovation in Japan and the U.S. drives growth, with disciplined underwriting and product design supporting profitability. Reinsurance and capital management enhance flexibility, while AI adoption improves efficiency and customer experience. Dividend growth and stable margins remain priorities.
-
A proposal for an independent board chairman was discussed but rejected by a large majority. All director nominees and key proposals, including auditor appointment and say-on-pay, received strong support. Share buybacks and succession planning were addressed in the Q&A.
-
Q1 2026 saw strong sales growth in Japan (+25.5%) and steady U.S. performance, with adjusted EPS up 6.6% year-over-year. Capital ratios remain robust, $1.3 billion was returned to shareholders, and new reinsurance initiatives in Japan signal future growth potential.
-
Strong sales growth in both Japan and the U.S. was driven by innovative products, expanded distribution, and disciplined capital management. The company remains focused on organic growth, technology investment, and maintaining its leading brand reputation, with continued shareholder returns and strategic flexibility.
Fiscal Year 2025
-
Q4 2025 saw strong adjusted earnings and robust sales growth in Japan, driven by new product launches, while the U.S. segment maintained solid premium growth and persistency. Capital deployment remained high, with record share repurchases and dividends, and guidance for 2026 remains stable.
-
Adjusted EPS rose 0.6% year-over-year, with strong capital and liquidity positions maintained. Japan premiums declined slightly, while U.S. premiums grew 4%; robust capital deployment included $800 million in share repurchases.
-
Q3 2025 saw strong adjusted EPS growth, robust sales in Japan (notably Miraito cancer insurance), and stable U.S. performance with group and dental products leading. Capital deployment was significant, and guidance remains positive for both markets.
-
Adjusted EPS grew 15.3% year-over-year, driven by reserve remeasurement gains and strong segment margins. Capital position remains robust, with $1B in stock repurchases and $309M in dividends paid. Liquidity and leverage ratios are well above targets.
-
Q2 2025 saw strong sales growth in Japan, especially in cancer insurance, and steady U.S. performance, with robust capital returns to shareholders. The Miraito product drove significant momentum, and digital transformation initiatives are underway. Guidance remains cautious but optimistic.
-
Adjusted EPS was flat year-over-year at $1.66, with strong sales growth in Japan and the U.S. driven by new product launches and robust capital management. The company returned $1.2 billion to shareholders and expects continued growth in 2025.
-
Strong financial results in 2024 were driven by robust profit margins in Japan and steady growth in the U.S., supported by product innovation, multi-channel distribution, and disciplined capital management. Strategic focus remains on expanding within existing accounts, optimizing broker relationships, and targeting younger customers in Japan.
Fiscal Year 2024
-
Strong 2024 results featured double-digit EPS growth, record Japan margins, and robust capital returns. Outlook for 2025 anticipates margin pressure from lower floating rate income and continued disciplined growth, with new product launches in Japan and U.S. platform improvements expected to drive future performance.
-
Celebrating 50 years in Japan and on the NYSE, the company outlined strategic growth plans for both markets, including new product launches, organizational transformation, and digital initiatives. Financial guidance targets steady premium growth, robust margins, and continued capital returns, supported by disciplined risk and investment management.
-
Adjusted EPS rose 17.4% to $2.16 despite a GAAP loss from FX impacts, with strong sales growth in Japan (12.3%) and the U.S. (5.5%). Capital ratios remain robust, and guidance for benefit ratios and margins improved due to favorable trends.
-
Q2 2024 saw strong adjusted EPS growth, robust margins, and solid capital ratios, with Japan's new product launch driving sales and the U.S. segment showing improved persistency and profitability. Management expects continued growth, disciplined expense control, and strong capital deployment.